Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3890197)

Published in Clin Orthop Relat Res on February 01, 2014

Authors

Ibrahim J Raphael1, Eric H Tischler, Ronald Huang, Richard H Rothman, William J Hozack, Javad Parvizi

Author Affiliations

1: Orthopaedic Research at the Rothman Institute, Thomas Jefferson Hospital, Philadelphia, PA, USA.

Associated clinical trials:

A Different Approach to Preventing Thrombosis (ADAPT) | NCT02774265

Articles cited by this

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol (1992) 60.45

Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet (2000) 4.38

Oral anticoagulant drugs. N Engl J Med (1991) 3.64

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med (1996) 2.22

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97

Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am (2001) 1.87

Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res (2008) 1.82

Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br (1997) 1.76

In hospital complications after total joint arthroplasty. J Arthroplasty (2008) 1.69

Does anticoagulation do more harm than good?: A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty (2003) 1.59

Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br (2006) 1.56

Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res (1996) 1.48

Does "excessive" anticoagulation predispose to periprosthetic infection? J Arthroplasty (2007) 1.45

American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am (2009) 1.34

Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am (1997) 1.16

Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br (2012) 1.07

Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty (2009) 1.07

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med (2002) 1.00

A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty (2001) 0.97

The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br (2009) 0.97

Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am (1986) 0.96

Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop (2012) 0.95

Overdiagnosis of pulmonary embolism: evaluation of a hypoxia algorithm designed to avoid this catastrophic problem. Clin Orthop Relat Res (2012) 0.94

The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am (1997) 0.91

The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res (2006) 0.90

Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty (1987) 0.87

Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment. Instr Course Lect (2008) 0.87

Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost (1997) 0.84

A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. J Arthroplasty (2003) 0.79

Aggressive Anticoagulation after TJA: an evaluation of the ACCP guidelines for Thromboprophylaxis. J Long Term Eff Med Implants (2007) 0.79

Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin. Am J Orthop (Belle Mead NJ) (2006) 0.79

Re: Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty (2010) 0.78

Comparative risk of early postoperative pulmonary embolism after cemented total knee versus total hip arthroplasty with low-dose warfarin prophylaxis. Am J Knee Surg (1996) 0.77

VTE prevention in major orthopedic surgery. Cleve Clin J Med (2008) 0.77

The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest (1998) 0.77

Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. J Arthroplasty (2012) 0.77

Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty (2008) 0.77

Articles by these authors

Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin Orthop Relat Res (2003) 12.86

Insall Award paper. Why are total knee arthroplasties failing today? Clin Orthop Relat Res (2002) 5.19

Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res (2008) 5.05

Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty (2008) 4.11

Economic burden of periprosthetic joint infection in the United States. J Arthroplasty (2012) 4.01

Anterior femoroacetabular impingement: part II. Midterm results of surgical treatment. Clin Orthop Relat Res (2004) 3.93

Anterior femoroacetabular impingement: part I. Techniques of joint preserving surgery. Clin Orthop Relat Res (2004) 3.46

Diagnosis of periprosthetic infection. J Bone Joint Surg Am (2006) 3.04

International consensus on periprosthetic joint infection: description of the consensus process. Clin Orthop Relat Res (2013) 2.93

Metal on metal: is it worth the risk? J Arthroplasty (2010) 2.76

Cell count and differential of aspirated fluid in the diagnosis of infection at the site of total knee arthroplasty. J Bone Joint Surg Am (2008) 2.74

Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res (2009) 2.45

Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty (2009) 2.40

Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem (2003) 2.25

Operating room traffic is a major concern during total joint arthroplasty. Clin Orthop Relat Res (2012) 2.18

Modular taper junction corrosion and failure: how to approach a recalled total hip arthroplasty implant. J Arthroplasty (2013) 2.13

The direct and indirect costs to society of treatment for end-stage knee osteoarthritis. J Bone Joint Surg Am (2013) 2.12

Diagnosing periprosthetic joint infection: has the era of the biomarker arrived? Clin Orthop Relat Res (2014) 2.11

Custom-fit total knee arthroplasty (OtisKnee) results in malalignment. J Arthroplasty (2008) 2.11

Orthopaedic surgeon workforce and volume assessment for total hip and knee replacement in the United States: preparing for an epidemic. J Bone Joint Surg Am (2008) 2.09

Total joint arthroplasty: When do fatal or near-fatal complications occur? J Bone Joint Surg Am (2007) 2.07

Prospective randomized study of two surgical approaches for total hip arthroplasty. J Arthroplasty (2010) 2.03

Criteria used by medical students to rank orthopedic surgery residency programs. Am J Orthop (Belle Mead NJ) (2006) 2.01

The role of patient restrictions in reducing the prevalence of early dislocation following total hip arthroplasty. A randomized, prospective study. J Bone Joint Surg Am (2005) 1.95

Safety of simultaneous bilateral total knee arthroplasty. A meta-analysis. J Bone Joint Surg Am (2007) 1.89

Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells (2003) 1.82

Surgical treatment of limb-length discrepancy following total hip arthroplasty. J Bone Joint Surg Am (2003) 1.81

Muscle damage during MIS total hip arthroplasty: Smith-Petersen versus posterior approach. Clin Orthop Relat Res (2006) 1.69

In hospital complications after total joint arthroplasty. J Arthroplasty (2008) 1.69

The value of intraoperative Gram stain in revision total knee arthroplasty. J Bone Joint Surg Am (2009) 1.58

The 2012 Chitranjan Ranawat award: intraarticular analgesia after TKA reduces pain: a randomized, double-blinded, placebo-controlled, prospective study. Clin Orthop Relat Res (2013) 1.58

American Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis of periprosthetic joint infections of the hip and knee. J Bone Joint Surg Am (2011) 1.57

Total hip arthroplasties: what are the reasons for revision? Int Orthop (2007) 1.55

Ninety-day mortality after bilateral hip arthroplasty. J Arthroplasty (2006) 1.54

The Mark Coventry Award: diagnosis of early postoperative TKA infection using synovial fluid analysis. Clin Orthop Relat Res (2011) 1.54

The noisy ceramic hip: is component malpositioning the cause? J Arthroplasty (2008) 1.53

The natural progression of synovial fluid white blood-cell counts and the percentage of polymorphonuclear cells after primary total knee arthroplasty: a multicenter study. J Bone Joint Surg Am (2013) 1.53

Failure following revision total knee arthroplasty: infection is the major cause. Int Orthop (2010) 1.53

Revision total knee arthroplasty infection: incidence and predictors. Clin Orthop Relat Res (2010) 1.50

Diagnosis of periprosthetic joint infections of the hip and knee. J Am Acad Orthop Surg (2010) 1.50

Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure. Clin Orthop Relat Res (2011) 1.48

Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. J Arthroplasty (2010) 1.47

Periprosthetic infection due to resistant staphylococci: serious problems on the horizon. Clin Orthop Relat Res (2009) 1.46

Preoperative anemia in total joint arthroplasty: is it associated with periprosthetic joint infection? Clin Orthop Relat Res (2012) 1.46

Does "excessive" anticoagulation predispose to periprosthetic infection? J Arthroplasty (2007) 1.45

The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J Arthroplasty (2009) 1.44

Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J Bone Joint Surg Am (2017) 1.44

Do ceramic femoral heads reduce taper fretting corrosion in hip arthroplasty? A retrieval study. Clin Orthop Relat Res (2013) 1.44

In vivo degradation of polyethylene liners after gamma sterilization in air. J Bone Joint Surg Am (2005) 1.43

The alpha-defensin test for periprosthetic joint infection outperforms the leukocyte esterase test strip. Clin Orthop Relat Res (2015) 1.42

Does intraoperative fluoroscopy improve component positioning in total hip arthroplasty? Orthopedics (2015) 1.40

A simple, cost-effective screening protocol to rule out periprosthetic infection. J Arthroplasty (2008) 1.38

Microbiological, clinical, and surgical features of fungal prosthetic joint infections: a multi-institutional experience. J Bone Joint Surg Am (2009) 1.38

Primary total hip arthroplasty with an uncemented femoral component: a long-term study of the Taperloc stem. J Arthroplasty (2004) 1.38

Molecular markers for diagnosis of periprosthetic joint infection. J Arthroplasty (2011) 1.37

Squeaking hips. J Bone Joint Surg Am (2008) 1.36

Vancomycin covalently bonded to titanium alloy prevents bacterial colonization. J Orthop Res (2007) 1.35

Demographic factors affecting long-term outcome of total hip arthroplasty. Clin Orthop Relat Res (2003) 1.35

The use of a constrained acetabular component to treat instability after total hip arthroplasty. J Bone Joint Surg Am (2003) 1.34

The use of receiver operating characteristics analysis in determining erythrocyte sedimentation rate and C-reactive protein levels in diagnosing periprosthetic infection prior to revision total hip arthroplasty. Int J Infect Dis (2009) 1.34

Staged revision for knee arthroplasty infection: what is the role of serologic tests before reimplantation? Clin Orthop Relat Res (2009) 1.34

American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am (2009) 1.34

Successful identification of pathogens by polymerase chain reaction (PCR)-based electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) in culture-negative periprosthetic joint infection. J Bone Joint Surg Am (2012) 1.34

Unplanned readmission after total joint arthroplasty: rates, reasons, and risk factors. J Bone Joint Surg Am (2013) 1.32

Two-stage exchange knee arthroplasty: does resistance of the infecting organism influence the outcome? Clin Orthop Relat Res (2010) 1.28

Infection control rate of irrigation and débridement for periprosthetic joint infection. Clin Orthop Relat Res (2011) 1.26

Mark B. Coventry Award: synovial C-reactive protein: a prospective evaluation of a molecular marker for periprosthetic knee joint infection. Clin Orthop Relat Res (2012) 1.25

Symptomatic pulmonary embolus after joint arthroplasty: stratification of risk factors. Clin Orthop Relat Res (2013) 1.25

Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg (2009) 1.25

Frank Stinchfield Award. Titanium surface with biologic activity against infection. Clin Orthop Relat Res (2004) 1.25

Impact of socioeconomic factors on outcome of total knee arthroplasty. Clin Orthop Relat Res (2014) 1.24

Diagnosis of periprosthetic joint infection. J Arthroplasty (2013) 1.24

The effect of stem design on the prevalence of squeaking following ceramic-on-ceramic bearing total hip arthroplasty. J Bone Joint Surg Am (2010) 1.24

The Chitranjan Ranawat Award: Should prophylactic antibiotics be withheld before revision surgery to obtain appropriate cultures? Clin Orthop Relat Res (2014) 1.23

Early mortality after modern total hip arthroplasty. Clin Orthop Relat Res (2008) 1.23

2006 Otto Aufranc Award Paper: significance of in vivo degradation for polyethylene in total hip arthroplasty. Clin Orthop Relat Res (2006) 1.23

Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty (2011) 1.22

The inhibition of Staphylococcus epidermidis biofilm formation by vancomycin-modified titanium alloy and implications for the treatment of periprosthetic infection. Biomaterials (2008) 1.21

Periprosthetic infection: where do we stand with regard to Gram stain? Acta Orthop (2009) 1.21

Complications associated with reimplantation after girdlestone arthroplasty. Clin Orthop Relat Res (2003) 1.21